| Literature DB >> 25185093 |
Emil J Freireich1, Peter H Wiernik2, David P Steensma3.
Abstract
Studies of the leukemias in the laboratory and in the clinic have generated many new concepts and therapies that will undoubtedly continue to be rapidly applied to the other forms of systemic cancer, particularly the concept of narrowly targeted personalized therapy that has proven so effective in CML. It seems likely that other subtypes of leukemia will eventually approach the success achieved with APL, CML, and pediatric ALL.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25185093 DOI: 10.1200/JCO.2014.57.1034
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544